SHARE
COPY LINK

CANCER

EU discard GM cancer report from French scientist

The European Food Safety Authority said Thursday it cannot accept an "inadequate" report by a French scientist on a link between cancer and genetically modified corn.

EU discard GM cancer report from French scientist
Photo: Mike Atkins

The EFSA said an initial review showed that the "design, reporting and analysis of the study … are inadequate," meaning it could not "regard the authors' conclusions as scientifically sound."

Given these shortcomings, the EFSA called on the author of the study, French scientist Gilles-Eric Seralini, to provide additional information before a second, final review is completed by the end of this month.

Seralini's team at France's University of Caen found that rats develop tumours when fed US agribusiness giant Monsanto's NK603 corn, or when exposed to one of the company's weedkillers used with it, containing glyphosate.

The scientist insisted Thursday he would not give the EFSA any additional information until it first detailed the basis of its own assessment.

"It is absolutely scandalous that (EFSA) keeps secret the information on which they based their evaluation" of NK603 and the pesticide, he said.

"In any event, we will not give them anything. We will put the information in the public domain when they do," Seralini told AFP.

NK603 was developed by Monsanto to make it resistant to the Monsanto herbicide Roundup, enabling farmers to use the weedkiller just once in the crop's life-cycle, enabling substantial savings.

Seralini and his team say their experiment in GM food is the first to follow rats through their lifespan, as opposed to just 90 days, but other experts have also questioned its methodology, results and relevance to humans.

EFSA, which reviews the use and authorisation of GMOs (Genetically Modified Organisms), said that "based on the information published by the authors … it does not see a need to re-examine its previous safety evaluation of maize NK603 nor to consider these findings in the ongoing assessment of glyphosate."

In May, the EFSA said a temporary French ban on another Monsanto corn, MON810, was not properly based on scientific evidence.

"Based on the documentation submitted by France, there is no specific scientific evidence, in terms of risk to human and animal health or the environment," EFSA said of the French position.

France, like many EU countries, has a long record of opposition to GM foods but the pressures on farmers in terms of cost are immense, driving their increasing use, especially in emerging economies such as China and Brazil.

EFSA listed a series of concerns it had with Seralini's findings, among them that the type of rat used "in the two-year study is prone to developing tumours during their life expectancy of approximately two years.

"This means the observed frequency of tumours is influenced by the natural incidence of tumours typical of this strain, regardless of any treatment. This is neither taken into account nor discussed by the authors."

Environmental groups attacked the EFSA action, saying it was not doing enough on its own to test GM foods while condemning the work of others.

The "EFSA fails to convince us that they are putting public safety before the interests of agribusiness biotech industry," said Mute Schimpf of Friends of the Earth.

"Instead of dismissing peer-reviewed independent research they should be asking themselves why they don't demand long term safety tests for genetically modified foods," Schimpf said.

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

HEALTH

Why cancer patients in Spain are changing address to stay alive

Almost half of all oncologists in Spain are reporting huge disparities between different regions in terms of patient access to the latest life-saving cancer treatments, spurring many patients to pack up and move (at least on paper).

Why cancer patients in Spain are changing address to stay alive
Photos: AFP

Time is of the essence when it comes to cancer and stopping it in its tracks.

But in Spain, a country where bureaucratic holdups are part and parcel of daily life, the repercussions attached to slow public service delivery in the health sector can prove lethal for some.

Spain’s Society of Oncology (SEOM) has just released a study that highlights the huge disparity in waiting times for newly approved cancer medications between the country’s different autonomous communities.

The timeframe from which a groundbreaking treatment is green lighted by Spain’s Ministry of Health to the moment it reaches a cancer patient in hospital varies between 5 to 17 months on average.

The wait is influenced by factors such as where the hospital is located in Spain, whether or not the regional health department has decided to incorporate the new medication into its cancer treatment and even the individual hospital’s modus operandi.

READ MORE:

With a one and half-year wait obviously not an option for anyone with the disease, especially those which are particularly aggressive, patients are preferring to pack their bags and move to an address where the holdups are far less.

For this they need to be registered (empadronados) at a municipality that falls within the catchment area of the hospital that can get them the drugs faster.

Technically their names will have to be on a rental contract or title deeds in the desired location to be able to do so, although this can also be achieved in many regions if a person living at said address authorises that they be included in the ‘padrón’.

A total of 84 public hospitals from all of Spain’s 17 autonomous communities (as well as the autonomous city of Ceuta) took part in the study, with 11 new cancer medications and 5 cancer biomarkers (a substance or process that helps to diagnose cancer) used as the basis of the research.

A total of 43 percent of oncologists surveyed told SEOM they had patients who were having to wait excessively long to receive the most cutting-edge treatment and diagnosis methods theoretically available to them through the public system, with some practitioners citing three-year-long holdups for prescriptions that have already been approved by medical authorities.

In fact, the study initially encompassed 146 hospitals across Spain, but 42 percent of them failed to get back to SEOM with the relevant information.

The same confusion that envelops many bureaucratic processes in Spain has seeped into the country’s health system, the research reveals.

In this case, there’s no homogenous nationwide policy or body to call on or complain to. Sometimes it’s the hospital that decides, in other cases it’s the region’s health department, making it unclear for people who can’t afford the wait.

Perhaps for this reason SEOM hasn’t revealed where exactly cancer patients can get the latest treatment fast and easy, as it can vary enormously even within the same city or town.

Even though Spain’s public health system is highly regarded worldwide (9th best internationally in 2015, 19th in 2018 according to The Lancet), the evidence suggests these cancer treatment holdups are nothing new.

Cancer sufferers have been ‘fudging’ their address for years as the only solution available to them for the currently inefficient system, other than actually moving to another part of Spain to sidestep the bureaucratic wait.

Begoña Barragán, president of the Spanish Group of Cancer Patients (GEPAC) told online daily Público she had at one point had 17 patients registered at her home address in order for them to gain access to her local hospital, which offered far shorter waiting periods than on average in Spain.

Her organization encompasses 70 associations across the country which have helped other cancer patients do the same.

“I remember one local minister once warning me ‘I don’t want to find out that you’ve been doing this in our region’, to which I replied ‘don’t worry, you won’t find out,” Barragán told Público.

“None of this has anything to do with medical reasons, it’s all due to administrational and financial causes. Doctors themselves will always offer up the best treatment if it’s up to them.

“This is a post code lottery, a game of chance”.

With this strand of unequal health service delivery increasingly under scrutiny, Spain’s Ministry of Health has shifted responsibility to the country’s autonomous communities, saying it’s up to them to find a solution.

But cancer groups and Spain’s health patient ombudsman are calling instead for a system that is as systematic as paying taxes.

“The rights to health service access, to be cured, to save lives cannot be determined by the place where you live, says the president of Defensor del Paciente Carmen Flores.

“That’s serious discrimination.

“Therefore, Spain’s Ministry of Health must create some order among the autonomous communities, that’s why they’re given funds from the national budget after all”.
 

SHOW COMMENTS